← Leaderboards
Sigrid Stroobants
Molecular Targeting Technologies, Inc.
$723,737
Attributed
$2,171,210
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $585.1K · FY2019–22$1M$750K$500K$250K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$2,171,210 · 1
By mechanism
R01$2,171,210 · 1
Top collaborators
- Koon Y Pak4 shared
- Leonie Wyffels4 shared
Most similar at Molecular Targeting Technologies, Inc.
Same institution · by research overlap
- Leonie Wyffels$723,737
- Jeffrey Mattis$222,581
Others in their field
Other Emerging Leaders on “Adverse Effects”
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Kristin Aillon · Midwest Research Institute$23,644,534
- Abraham Aizer Brody · New York University School Of Medicine$21,887,280
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$21,828,548
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
Research focus
Adverse EffectsAnatomic ImagingAnatomyAnimal ModelApoptoticBaseBelgiumBindingBiodistributionCancer EtiologyCancer ImagingCancer TherapyCell DeathCellsCessation Of LifeChemotherapyClinical ImagingClinical PracticeClinical ResearchClinical TranslationCollaborationsColon Cancer PatientsColorectal CancerAcute Toxicity
Grant awards (4)
Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin$500,963
R01 · FY2022 · CA
Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin$514,387
R01 · FY2021 · CA
Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin$570,747
R01 · FY2020 · CA
Early Prediction of Tumor Response to Treatment: Clinical Translation of [99mTc]-Duramycin$585,113
R01 · FY2019 · CA